WO2006125285B1 - Insulin sensitization to slow down pubertal tempo and to augment pubertal growth - Google Patents
Insulin sensitization to slow down pubertal tempo and to augment pubertal growthInfo
- Publication number
- WO2006125285B1 WO2006125285B1 PCT/BE2006/000060 BE2006000060W WO2006125285B1 WO 2006125285 B1 WO2006125285 B1 WO 2006125285B1 BE 2006000060 W BE2006000060 W BE 2006000060W WO 2006125285 B1 WO2006125285 B1 WO 2006125285B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutically acceptable
- pubertal
- polymorphs
- solvates
- insulin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
In accordance with the purpose of the invention, as embodied and broadly described herein, the invention is broadly drawn to a new method of treatment, the use of agents to manufacture a composition of treatment or the composition of treatment for the prevention of rapidly progressive puberty, the prevention of early menarche or the modulation, more particularly the delay, of the tempo of puberty in a female mammal, preferably a human girl, and the disorders related thereto. In a particular embodiment the present invention involves the use of at least one insulin-sensitizing agent such as metformin, any of the polymorphs of metformin or a pharmaceutically acceptable salt thereof for the preparation of a composition of treatment to modulate the tempo of pubertal progression in a girl.
Claims
AMENDED CLAIMS received by the International Bureau on 03 November 2006 (03.11.2006)
1) The use of af least one biguanide or glitazone (thiazolidinedione) insulin-sensitizing agent or aminoguanidine or a pharmaceutically acceptable sail, solvate or polymorph (hereof for the preparation of a composition of treatment to slow down the tempo of pubertal progression in a warm-blooded animal.
2) The use of claim 1, for the preparation of a composition of a treatment to slow down the- tempo of pubertal progression to prolong the pubertal growth in a warm-blooded animal.
3} The use of claim 1, to increase pubertal height gain or adult stature.
4) The use of claim 1 or 2, wherein the warm-blooded animal is a mammal.
5) The use of any of claim 1 to 3,. wherein the mammal is a human.
6) The use of any of claim 1 to 4, wherein the human is a boy. . 7} The use of any of claim 1 to 4, wherein the human is a girl.
8) The use of any of the claims 1 to 7, wherein the msulm-sensitizin g. compound is selected of the group consisting of metformin, rosiglitazone, pioglitazone, troglitazone, englitazone, (argretin, phenformin and bufomin , or pharmaceutically acceptable salts, solvates or polymorphs thereof.
9) The use of any of the claims 1 to 7, wherein the insulϊn-sensitizing compound is selected of the group consisting of metformin, rosiglitazone, pioglitazone, troglitazone, englitazone targretin , phenformin, CLX-0921, BLX-1002, tesaglitazar, oxegtitazar and buformm or pharmaceuticady accepiable salts, solvates or polymorphs.
10) The use of any of the claims 1 to 6 wherein the insulin-sensitizing compound is selected of the group consisting of 5-[[4-]2-{3-methyl-2-pyridinyl)ethoxy]phen.yl]methyI]- 2,4- Thiazolidinedione , 5-[4-[2-(5-ethyl-2-pyridinyl}-2-hydroxyethoxy]phenyl]methy]]-2,4- Thiazolidinedione, 5-[[4-[2-I5-(l-hydroxyethyl )-2-pyridmyl]ethoxy]phenyl ]methyl]]-2,4- Thiazolidinedione, 5-[[4-[2-(5-acetyl-2-pyriumyl)ethoxy]phenyl]methyl]]-2,4- li inedione 5-[[4-[2(methy]-2-pyridinylamino) ethoxy]phenyl]- methy]]-2,4- thiazolidine. dione maleate, 5-[4-(l-memy]cyclohexylmethoxy)benzyl ]-thiazolidine-2,4-dione and ([ or ~D)-5-[4-(6-methoxy-1-H-benzimidazol-2-ylmethoxy) benzyl [thiazoline-2,4-dione hydrochloride (CI-1037/CS-011) or pharmaceutically acceptable salts, solvates or polymorphs- thereof.
11) The use of any of the claims 1 to 7, wherein the insulin sensitizing compound has the general structure formula:
12) The use of any of the claims 1 to 1, wherein the insulin-sensitizing compound has the general structure formula :
13) The use of any of the claims 1 to 7, -wherein the insulin-sensitizing compound has the general structure formula
its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, its pharmaceutically acceptable solvates, -wherein represents an optional double bond; Y represents oxygen, sulfur or NR, wherein R represents hydrogen or alkyl,; Z represents oxygen or surfer, R1, R2, R3 and R4 may be same or different and independently represent hydrogen, halogen, hydroxy, nitio, cyano, formyl, amino, alkyl, or alkoxy, A represents a bond or substituted or unsubstituted aryl, heterocyclyl or heteroaryl ring X represents an alpha amino carboxylo acid or aplha amino cariboxylic acid derivative bonded to A or Y through its aptha side chain.
14) The use of any of the claims 1 to 7, wherein the sensitizing agent is metformin or a pharmaceutically acceptable salts, solvates or polymorphs thereof.
15) The use- of any of the claims 1 to 7 wherein the sensitizing agent is rosiglitazone or a pharmaceutically acceptable salts, solvates or polymorphs thereof.
16) The use of any of ibe claims I to- 7, wherein the- sensitizing agent is pioglitazone or a pharmaceutically acceptable salts, solvates 07 polymorphs thereof
17) The- use of any of ihe claims 1 to7 wherein the senzitizing agent is C1-1037/CS-011 or a pharmaceutically acceptable salts, solvates or polymorphs thereof
18) The use of any of the claims 1 to 1, wherein the sensitizing agent is ammoguanidine or a pharmaceutically acceptable sails, solvates or polymorphs thereof
19) The use of any of the claims 1 to 7, wherein the sensitizing agent is conjugated linoliec acid or a pharmaceutically acceptable derivative thereof
20} The use of the claim 1 to 19, for the preparation of a composition further comprising a suitable pharmaceutical earner and/or excipient
21) The use of the claims I to 20, wherein the warm-blooded animal is not obese.
22) The use of the claims I to 21, wherein the warm-blooded animal is ohcse.
23) The use of insulin sensitizer which is a KPARy agonist selected from the group consisting of BRL 49653, troglitazone, pioglitazone, ciglitazone, WAY- 120,744, englitazone, AD 5075, darglitazone , G1-26257B, SB 217092, SB 236636, SB 217092, SB 219994, tesaglitazar, CLX- 0921, BLX- 1002, Metaglidasen ((-) (3-trihalomethylphenoxy) (4-halophenyl) acetic) and SB 219993 or a pharmaceutically acceptable salt, solvate or polymorph, thereof for the preparation of a composition of a treatment to slow down the tempo of pubertal progression or to prolong the pubertal growth in a warm-blooded animal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0510469.0 | 2005-05-23 | ||
| GBGB0510469.0A GB0510469D0 (en) | 2005-05-23 | 2005-05-23 | Insulin sensitization to slow down pubertal tempo and to augment pubertal growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2006125285A1 WO2006125285A1 (en) | 2006-11-30 |
| WO2006125285B1 true WO2006125285B1 (en) | 2007-01-11 |
Family
ID=34834482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/BE2006/000060 WO2006125285A1 (en) | 2005-05-23 | 2006-05-23 | Insulin sensitization to slow down pubertal tempo and to augment pubertal growth |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB0510469D0 (en) |
| WO (1) | WO2006125285A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7040798B2 (en) | 2016-12-01 | 2022-03-23 | ミノリックス セラピューティクス エセ．エレ． | 5-[[4- [2- [5- (1-hydroxyethyl) pyridin-2-yl] ethoxy] phenyl] methyl] -1,3-thiazolidine-2 for treating non-alcoholic fatty liver disease ， 4-Zeon |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2462720C1 (en) * | 2011-10-10 | 2012-09-27 | Нина Викторовна Болотова | Method for describing nature of arrested sexual development in boys in puberty with growth retardation |
| WO2019234690A1 (en) * | 2018-06-06 | 2019-12-12 | Minoryx Therapeutics S.L. | Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts |
-
2005
- 2005-05-23 GB GBGB0510469.0A patent/GB0510469D0/en not_active Ceased
-
2006
- 2006-05-23 WO PCT/BE2006/000060 patent/WO2006125285A1/en active Application Filing
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7040798B2 (en) | 2016-12-01 | 2022-03-23 | ミノリックス セラピューティクス エセ．エレ． | 5-[[4- [2- [5- (1-hydroxyethyl) pyridin-2-yl] ethoxy] phenyl] methyl] -1,3-thiazolidine-2 for treating non-alcoholic fatty liver disease ， 4-Zeon |
Also Published As
| Publication number | Publication date |
|---|---|
| GB0510469D0 (en) | 2005-06-29 |
| WO2006125285A1 (en) | 2006-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010203352B8 (en) | Methods for treating vascular leak syndrome | |
| KR101179087B1 (en) | Human protein tyrosine phosphatase inhibitors and methods of use | |
| JP2010519181A5 (en) | ||
| AU2002246397B2 (en) | Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence | |
| AU2010271105C1 (en) | Compounds, compositions, and methods for preventing metastasis of cancer cells | |
| JP4175113B2 (en) | A therapeutic agent for depression containing an EP1 antagonist as an active ingredient | |
| AU754488B2 (en) | Method for treating diabetes employing an aP2 inhibitor and combination | |
| JP2005521642A5 (en) | ||
| US20140288134A1 (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| JP2004534035A5 (en) | ||
| JP2007531744A5 (en) | ||
| JP2008531520A5 (en) | ||
| JP2005537248A5 (en) | ||
| JP2011504935A5 (en) | ||
| WO2005080358A3 (en) | Rosiglitazone phosphate and polymorphic forms | |
| JP2005511608A5 (en) | ||
| US20180092883A1 (en) | Phosphatase inhibitors for treating ocular diseases | |
| EP2650287A1 (en) | Thiazole Derivative and use thereof as VAP-1 Inhibitor | |
| JP2006516251A5 (en) | ||
| WO2006125285B1 (en) | Insulin sensitization to slow down pubertal tempo and to augment pubertal growth | |
| JP6378179B2 (en) | Novel compound, detection agent and activity inhibitor of organic cation transporter 3 | |
| EP1306086A2 (en) | Use of thiazolidinediones for the treatment of atherosclerosis and eating disorders | |
| WO1998002159A1 (en) | Novel treatment of leptine resistance | |
| RU2002135079A (en) | HETEROCYCLIC COMPOUNDS | |
| JP2013507397A5 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| NENP | Non-entry into the national phase in: |
Ref country code: RU |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: RU |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 06741310 Country of ref document: EP Kind code of ref document: A1 |